Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.45 |
| ▸ | STK4 | Q13043 | 11/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745771 | 0.84 | LMNA (0.56) | EGFRERBB2STK4SRCLMNA | |
| SCHEMBL4745672 | 0.80 | EGFR (0.51) | EGFRERBB2STK4SRC | |
| SCHEMBL4744821 | 0.71 | EGFR (0.55) | EGFRERBB2STK4SRC | |
| SCHEMBL4744907 | 0.71 | EGFR (0.50) | EGFRERBB2SRCLMNA | |
| SCHEMBL15106963 | 0.68 | PTGDR2 (0.59) | PTGDR2LMNA | |
| SCHEMBL4742017 | 0.68 | SRC (0.59) | EGFRERBB2STK4SRC | |
| SCHEMBL4984379 | 0.66 | STK4 (0.48) | EGFRERBB2STK4SRCCYP3A4 | |
| SCHEMBL20204866 | 0.66 | SRC (0.46) | EGFRERBB2STK4SRC | |
| SCHEMBL24392117 | 0.66 | SRC (0.56) | EGFRERBB2SRC | |
| SCHEMBL6383704 | 0.66 | EGFR (0.78) | EGFRERBB2STK4SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | EGFR 3929/4885ERBB2 1069/4885STK4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.